Clinical Trial

Evaluation of the Efficacy and Safety of Megestrol Acetate in Preventing Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated August 19, 2025 (before its estimated July 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
To evaluate the efficacy of Megestrol Acetate Oral Suspension in Preventing Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy in Malignant Solid Tumor Patients
Trial Details
NCT Number NCT07130617
Lead Sponsor Changchun GeneScience Pharmaceutical Co., Ltd.
Conditions Efficacy, Safety, Megestrol Acetate, Adult Subject
Enrollment 132 participants
Start Date 2025-09-29
Primary Completion 2026-07-31 (estimated)
Study Completion 2026-07-31 (estimated)
Updated on ClinicalTrials.gov 2025-08-19